Inflamax Research (Canada)

Recent papers from Inflamax Research (Canada)

1. Interfollicular Plasmacytosis and Hyperplastic Germinal Centers in Idiopathic Multicentric Castleman Disease, Idiopathic Plasmacytic Lymphadenopathy SubtypeAmerican Journal of Hematology · 2026
2. Onset of efficacy of azelastine hydrochloride 0.15% nasal spray for allergic rhinitis in an environmental exposure chamberAnnals of Allergy Asthma & Immunology · 2024
3. Barrier‐forming, drug‐free nasal spray reduces allergic symptoms induced by house dust mite allergenClinical and Translational Allergy · 2023
4. Technical standards in allergen exposure chambers worldwide – an EAACI Task Force ReportAllergy · 2021
5. Safety of the standardized quality tree sublingual immunotherapy tablet: Pooled safety analysis of clinical trialsTyöväentutkimus Vuosikirja · 2021
6. Electronic Data Capture-Study Conduct, Maintenance and CloseoutJournal of the Society for Clinical Data Management · 2021
7. Electronic Data Capture-Selecting an EDC SystemJournal of the Society for Clinical Data Management · 2020
8. Perspectives in allergen immunotherapy: 2019 and beyondAllergy · 2019
9. Effect of olopatadine-mometasone combination nasal spray on seasonal allergic rhinitis symptoms in an environmental exposure chamber studyAnnals of Allergy Asthma & Immunology · 2018
10. A birch sublingual allergy immunotherapy tablet reduces rhinoconjunctivitis symptoms when exposed to birch and oak and induces IgG₄ to allergens from all trees in the birch homologous groupAllergy · 2018
11. Pharmacokinetics of intranasal olopatadine in the fixed-dose combination GSP301 versus two monotherapy intranasal olopatadine formulationsAllergy and Asthma Proceedings · 2018
12. Pharmacokinetics of intranasal mometasone in the fixed-dose combination GSP301 versus two monotherapy intranasal mometasone formulationsAllergy and Asthma Proceedings · 2018
13. Determination of Selected Chemical Levels in Room Air and on Surfaces after the Use of Cartridge- and Tank-Based E-Vapor Products or Conventional CigarettesInternational Journal of Environmental Research and Public Health · 2017
14. Allergen exposure chambers: harmonizing current concepts and projecting the needs for the future – an EAACI Position PaperAllergy · 2017
15. A Pilot Study Investigating Clinical Responses and Biological Pathways of Azelastine/Fluticasone in Nonallergic Vasomotor Rhinitis before and after Cold Dry Air ProvocationInternational Archives of Allergy and Immunology · 2017
16. A Phase 2 Exploratory Study of a Novel Interleukin-1 Receptor Inhibitor (EBI-005) in the Treatment of Moderate-to-Severe Allergic ConjunctivitisEye & Contact Lens Science & Clinical Practice · 2015
17. Weather and livestock risk factors for Escherichia coli O157 human infection in Alberta, CanadaEpidemiology and Infection · 2014
18. Double‐blind, placebo‐controlled, dose‐ranging study of new recombinant hypoallergenic Bet v 1 in an environmental exposure chamberAllergy · 2013